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AbstrAct
Introduction Antibiotic overuse drives antibiotic 
resistance. The optimal duration of antibiotic therapy for 
Gram-negative bacteraemia (GNB), a common community 
and hospital-associated infection, remains unknown and 
unstudied via randomised controlled trials (RCTs).
Methods and analysis This investigator-initiated, 
multicentre, non-inferiority, informatics-based point-of-
care RCT will randomly assign adult hospitalised patients 
receiving microbiologically efficacious antibiotic(s) for GNB to 
(1) 14 days of antibiotic therapy, (2) 7 days of therapy or (3) 
an individualised duration determined by clinical response 
and 75% reduction in peak C reactive protein (CRP) values. 
The randomisation will occur in equal proportions (1:1:1) on 
day 5 (±1) of efficacious antibiotic therapy as determined 
by antibiogram; patients, their physicians and study 
investigators will be blind to treatment duration allocation 
until the day of antibiotic discontinuation. Immunosuppressed 
patients and those with GNB due to complicated infections 
(endocarditis, osteomyelitis, etc) and/or non-fermenting 
bacilli (Acinetobacter spp, Burkholderia spp, Pseudomonas 
spp) Brucella spp, Fusobacterium spp or polymicrobial 
growth with Gram-positive organisms will be ineligible. 
The primary outcome is incidence of clinical failure at day 
30; secondary outcomes include clinical failure, all-cause 
mortality and incidence of Clostridiumdifficile infection in 
the 90-day study period. An interim safety analysis will be 
performed after the first 150 patients have been followed 
for ≤30 days. Given a chosen margin of 10%, the required 
sample size to determine non-inferiority is roughly 500 
patients. Analyses will be performed on both intention-to-
treat and per-protocol populations.
Ethics and dissemination Ethics approval was 
obtained from the cantonal ethics committees of all three 
participating sites. Results of the main trial and each of the 
secondary endpoints will be submitted for publication in a 
peer-reviewed journal.
Trial registration number This trial is registered at www. 
clinicaltrials. gov (NCT03101072; pre-results).
IntroductIon and ratIonale
Antibiotic resistance is growing at an 
alarming rate and is now considered by many 
governments to be one of the most serious 
global threats of the 21st century.1–3 The key 
driver of antibiotic resistance is antibiotic 
overuse,4 and patients who receive extended 
courses of broad-spectrum antibiotics are at 
significantly higher risk for later infections 
with difficult-to-treat, multidrug-resistant 
bacteria.5 6
No randomised controlled trial (RCT) 
evaluating the optimal duration of therapy 
for Gram-negative bacteraemia (GNB), a 
frequent community-associated and hospi-
tal-associated infection, has been published. 
Traditionally, guidelines have somewhat arbi-
trarily recommended long antibiotic courses 
of 2 weeks, even though patients with no 
structural complications may recover after 
only 5 days of therapy.7 Direct evidence is 
mounting that longer antibiotic courses leave 
PIRATE project: point-of-care, 
informatics-based randomised 
controlled trial for decreasing overuse of 
antibiotic therapy in Gram-
negative bacteraemia
Angela Huttner,1,2 Werner C Albrich,3 Pierre-Yves Bochud,4 Angèle Gayet-Ageron,5 
Anne Rossel,6 Elodie von Dach,1,2 Stephan Harbarth,1,2 Laurent Kaiser1 
to cite: Huttner A, Albrich WC, 
Bochud P-Y, et al.  PIRATE 
project: point-of-care, 
informatics-based randomised 
controlled trial for decreasing 
overuse of antibiotic 
therapy in Gram-negative 
bacteraemia. BMJ Open 
2017;7:e017996. doi:10.1136/
bmjopen-2017-017996
 ► Prepublication history for 
this paper is available online. 
To view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2017- 
017996).
Received 31 May 2017
Accepted 1 June 2017
For numbered affiliations see 
end of article.
Correspondence to
Dr Angela Huttner;  Angela. 
Huttner@ hcuge. ch
Protocol
Strengths and limitations of this study
 ► This large, multicentre randomised controlled trial 
will test the non-inferiority of shorter antibiotic 
courses for Gram-negative bacteraemia and thus 
provide clinicians with much-needed data from 
randomised patients on how to safely reduce 
antibiotic consumption.
 ► This trial provides proof-of-concept and safety 
data for individualising antibiotic durations in the 
treatment of Gram-negative bacteraemia.
 ► The trial will pilot electronic health record-guided 
patient-identification, randomisation and data-
transfer procedures at its principal site.
 ► Two substudies will explore (1) patient recall after 
oral versus written consent and (2) the external 
validity of the trial’s findings by observationally 
following the outcomes of excluded patients, 
respectively
 ► The lack of full blinding (eg, with dummy for short-
course arms) is a limitation to the study design.
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patients at risk of acquiring difficult-to-treat multiresis-
tant organisms. In one RCT comparing 8 to 15 days of 
antibiotic therapy for ventilator-associated pneumonia, 
multiresistant pathogens emerged significantly less 
frequently in those who had received 8 days of antibi-
otics.6 Indeed, given rising concerns over resistance, 
many physicians have reduced antibiotic durations for 
uncomplicated GNB to 7 days with no apparent untoward 
consequences.8
Although these shorter durations have not been directly 
studied, there is nonetheless mounting evidence that they 
do not increase patients’ risk of relapse or other complica-
tions: several randomised studies evaluating the optimal 
duration of antibiotic therapy for pyelonephritis,9 pneu-
monia,10–12 peritonitis13 14 and surgical site infections15 
have included patients with concurrent bloodstream 
infections (both Gram negative and positive). These have 
compared durations as short as 5 days with longer (7 or 
14 days) durations, and none demonstrated differences 
in the subset of patients with bacteraemia in clinical or 
microbiological outcomes.7 Nonetheless, none of these 
trials aimed specifically to assess the equivalence or the 
non-inferiority of shorter versus longer durations of anti-
biotic therapy.
Antibiotic durations could also be individualised, 
guided by clinical response as measured by objective 
markers, including inexpensive biomarkers such as C 
reactive protein (CRP).16 This acute phase protein is a reli-
able and highly sensitive marker of inflammation across 
different patient populations and infections.17–19 While 
procalcitonin has been studied in more than 20 RCTs as a 
biomarker to guide the duration of antibiotic therapy in 
severe infections20 21 and has indeed proved the concept of 
biomarker-guided therapy, observational and randomised 
studies16 22 have demonstrated no substantial differences 
in the ability of these two markers to reflect improvement 
(or worsening) in the clinical course of severe infections. 
Indeed, an RCT comparing the two markers head-to-head 
for guiding antibiotic therapy duration in sepsis found 
that a procalcitonin-based protocol was not superior to a 
CRP-based protocol, while no difference in morbidity or 
mortality was observed.16 CRP is substantially less expen-
sive and more accessible than procalcitonin across various 
clinical settings: many community hospitals do not offer 
or routinely perform the procalcitonin assay.
The increasing equipoise with regard to varying treat-
ment durations, the high incidence of Gram-negative 
bacteraemia (GNB), the relative ease of its diagnosis 
and the high stakes of antibiotic overconsumption in an 
ageing population combine to make antibiotic use for 
GNB an appropriate subject of study for a point-of-care 
(POC) randomised trial. We hypothesise that shorter 
antibiotic courses for GNB reduce antibiotic treatment 
days without increasing relapse rate or mortality.
objectIves
The trial’s primary objective is to determine whether 
shorter antibiotic courses (5–7 days) are non-inferior 
to a 2-week antibiotic course in the treatment of GNB. 
Secondary objectives are to determine whether antibiotic 
durations can be safely determined via a simple algo-
rithm employing clinical and laboratory (CRP) markers, 
whether shorter antibiotic courses for GNB will result 
in a decrease in antibiotic days, incidence of Clostridium 
difficile infection, emergence of bacterial resistance and 
length of hospital stay.
Methods and analyses
study design and setting
This investigator-initiated, analyst-blinded, POC RCT 
will enrol 500 hospitalised adult patients diagnosed with 
community-acquired or hospital-acquired GNB. The trial 
will take place at the Geneva University Hospitals (HUG; 
principal site), the Centre Hospitalier Universitaire 
Vaudois (CHUV) and the Cantonal Hospital St Gallen 
(KSSG; figure 1). The HUG, CHUV and KSSG perform 
roughly 59 000, 43 000 and 35 000 admissions per year, 
respectively; each has both a microbiology laboratory and 
a team of consulting infectious disease physicians avail-
able at all times.
study population and entry criteria
Potential study patients will be identified via both the 
laboratory and the electronic health record (EHR): in all 
of these hospital systems, the microbiology laboratory is 
required to report daily all positive blood cultures to the 
infectious disease consult team.
Inclusion criteria
 ► Age ≥18 years
 ► The presence of GNB in at least one blood culture 
bottle
 ► Treatment with a microbiologically efficacious 
antibiotic
Exclusion criteria
 ► Immunosuppression (including HIV infection 
with CD4 cell count ≤500/µL, haematopoietic 
stem-cell transplantation in the first month after 
transplantation and at any time before engraftment, 
neutropaenia in the 48 hours prior to randomisation, 
receipt of high-dose steroids (>40 mg prednisone or 
its equivalent) daily for >2 weeks) in the 2 weeks prior 
to randomisation
 ► GNB due to the following complicated infections:
 ► Endocarditis or other endovascular infection 
without a removable focus;
 ► Necrotising fasciitis;
 ► Osteomyelitis or septic arthritis;
 ► Confirmed prostatitis;
 ► Undrainable abscess or other unresolved sources 
requiring surgical intervention (eg, cholecystitis) 
at the time of enrolment;
 ► Central nervous system infections;
 ► Empyema;
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Figure 1 Trial sites: the HUG is the principal site; CHUV and KSSG are participating peripheral sites. CHUV, Centre Hospitalier 
Universitaire Vaudois; HUG, Geneva University Hospitals; KSSG, Catonal Hospital St Gallen.
 ► GNB due to non-fermenting bacilli (Acinetobacter 
spp, Burkholderia spp, Pseudomonas spp) Brucella 
spp, Fusobacterium spp or polymicrobial growth with 
Gram-positive organisms;
 ► Fever (≥38°C) or haemodynamic instability in the 
24 hours prior to recruitment.
Intervention
With day 1 defined as the first day of appropriate 
(microbiologically efficacious per antibiogram results) 
antibacterial therapy, patients will be randomised 1:1:1 on 
day 5 (±1) to one of the following three arms (figure 2):
 ► ‘Fixed long’ antibiotic course of 14 days (control 
arm);
 ► ‘Fixed short’ antibiotic course of 7 days (first 
intervention arm);
 ► ‘Individualised’ antibiotic course: starting on day 5, 
therapy will be discontinued after the patient has been 
afebrile for 48 hours and the CRP level has decreased 
from its peak by at least 75% (second intervention 
arm).
The rationale for our ‘fixed-short’ treatment arm of 7 
days derives from several observational studies suggesting 
the safety of shorter antibiotic durations (5–10 days) for 
patients with bacteraemia.7 23 24
CRP algorithm for the individualised-duration arm
The rationale for the individualised algorithm’s specific 
use of a 75% reduction in peak CRP values is based on 
an RCT of patients in intensive care units (ICUs) with 
severe sepsis or septic shock with or without bacter-
aemia.16 That study demonstrated that an even more 
restrictive algorithm (antibiotic stop once the CRP has 
decreased by ≥50% if peak CRP was ≥100 mg/L or once 
CRP is less than 25 mg/L if peak CRP was <100 mg/L) 
was safe and effective to reduce antibiotic use. This study 
additionally used a 7-day maximum duration of antibiotic 
therapy for non-bacteraemic patients while bacteraemic 
patients received at least 7 days of antibiotics.16 Our indi-
vidualised algorithm is slightly adapted in analogy to 
procalcitonin-based algorithms, which have been success-
fully tested in several RCTs and used ≥80% decreases of 
procalcitonin to discontinue antibiotic therapy.20 25–28 
Our slight modifications take into account the slower 
decrease of CRP values compared with procalcitonin after 
resolution of an infection27 29 and incorporate an addi-
tional safety margin compared with the study by Oliveira 
et al, which treated bacteraemic patients differentially.16 
Of note, if the CRP value has not decreased by 75% by 
day 14, the marker will no longer be used to guide the 
duration of therapy. In these cases, the duration will be 
determined by clinical judgement per usual practice.
Choice of antibiotic(s) and mode of administration
In all arms, the choice and mode of administration of 
antibiotic(s) will be left to the patient’s attending physi-
cian and consulting infectious disease specialist and thus 
will follow usual standards of care, determined primarily 
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Figure 2 Trial flow: day 1 is defined as the first day of microbiologically appropriate antibiotic therapy. Patients will be 
randomised on day 5 (±1) and followed until day 90.
by the three sites’ local institutional antibiotic therapy 
guidelines and antimicrobial resistance patterns. (Resis-
tance prevalences in these hospitals and communities are 
similar, and the sites’ treatment guidelines contain no 
significant discrepancies with respect to acceptable anti-
biotic treatment standards of uncomplicated GNB.)
De-escalation (from a broad-spectrum to a more 
narrow-spectrum antibiotic), switches from intravenous to 
oral antibiotic therapy or from intermittent to continuous 
infusions or vice-versa, will be allowed per current standard 
practice. Study investigators will not interfere with these clin-
ical decisions but will collect detailed data on all therapeutic 
management for later subanalyses. Although in Geneva 
randomisation and subsequent discontinuation of antibiotic 
therapy according to treatment arm will occur through the 
EHR, at all sites study investigators will also not interfere with 
attending physicians’ decisions to prolong therapy should a 
patient’s clinical condition worsen. (See sections on statis-
tical analysis and sample size calculation.)
randomisation
We determine day 5 as the appropriate randomisation 
point because this is the usual timing of the study’s and 
clinicians’ essential question:
Now that my patient has been stabilized and appears 
to be improving, when can I safely discontinue 
antibiotic therapy?
General principles and peripheral site randomisation procedures
Randomisation will be based on investigator-blinded 
blocks of randomly varying size to protect against poten-
tial predictability of treatment assignments. Blocks will 
contain 3, 6, 9 or 12 allocations. Randomisation will be 
stratified by study site, given that the three sites do not 
share a common EHR system and that site launches will 
be staggered (HUG will be the first site to launch; CHUV 
and KSSG will follow). For randomisation at HUG, see the 
next section. For randomisation at CHUV and KSSG, a 
statistician not involved in the study analysis will produce 
the randomisation list prior to the initiation of the study; 
the blocks’ order will be generated by use of a comput-
er-based randomised number system, and the allocation 
implemented by means of sealed, opaque envelopes. The 
statistician will keep copies of the randomisation list.
POC randomisation through the electronic health record at HUG
In POC trials, the extent of the EHR’s involvement in 
randomisation is variable: on one end of the spectrum, the 
EHR simply provides an automatic alert to a prescribing 
physician making her aware of the existence of the POC 
trial and the patient’s likely eligibility for it while simul-
taneously alerting a study investigator of the patient. At 
the other end of the spectrum, the EHR provides such 
alerts and, according to a physician-triggered EHR work-
flow, ultimately performs the actual randomisation with 
treatment assignment.
In the present study, through the work of information 
technology (IT) specialists at HUG, this principal study site 
will implement a fully EHR-integrated process (figure 3) 
using HUG’s ‘Dossier patient informatique’ (DPI), with 
an initial, early alert to the study team at the moment the 
positive blood culture is registered in the EHR and auto-
matic alerts for the treating physician at POC and study 
personnel once the patient enters the eligibility window. 
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Figure 3 Electronic-healthcare record workflow for patient identification, randomisation and follow-up in Geneva. The EHR 
workflow is outlined in red, the control (‘back-up’) workflow in grey. Grey arrows indicate safety valves; these cover all points 
at which the EHR workflow could malfunction. In this hypothetical case, the patient has been randomised to the control arm 
(antibiotic therapy duration of 14 days). EHR, electronic health record.
Study personnel will be notified to (1) provide information 
to the patient, (2) verify study inclusion criteria and then 
(3) approve the EHR-based randomisation.
At the moment of randomisation, the EHR will (1) 
automatically place a note of participation in the medical 
record and (2) establish the duration of the patient’s 
antibiotic prescription (7 or 14 days or the individual-
ised duration, which will also be determined within the 
EHR, as it houses temperature and CRP data). On the 
predetermined day of antibiotic discontinuation, both 
physicians and nurses will receive alerts regarding that 
discontinuation. These alerts will be repeated until the 
physician electronically signs his acknowledgement of the 
discontinuation.
The control workflow
Importantly, the current study focus of GNB provides an 
ideal occasion for piloting and testing this process since, 
in reality, the study team will already be well aware of all 
patients hospital-wide with any GNB, given the established 
daily communication between microbiology laboratories 
and infectious disease teams described above. There will 
thus be a ‘control’ workflow shadowing the automated 
EHR workflow at all times, with safety valves present at all 
workflow nodes (figure 3).
The EHR-determined randomisation procedure
The EHR will be programmed to randomise using the 
same principles described above: randomisation will 
be based on randomly varying blocks with 3, 6, 9 or 12 
treatment duration assignments. The bioinformatics 
specialist leading the informatics component of this 
trial will keep a copy of the EHR’s randomisation list, as 
will a designated, unblinded member of the study team 
(control workflow).
blinding
‘Ad terminum’ blinding of patients, attending physicians and 
investigators
The blinding of patients, hospital staff and designated 
trial investigators to assigned treatment duration will be 
key to avoiding the introduction of bias in the follow-up/
management of patients between study arms. It is conceiv-
able that the knowledge that one’s patient will receive a 
shorter course of antibiotics could result in defensive 
medicine, with that patient’s receiving ‘special treatment’ 
such as additional surveillance blood cultures and/or 
imaging tests just before antibiotic discontinuation. For 
this reason, we will carry blinding of patients, treating 
hospital staff and designated investigators through 
the furthest study point possible. These parties will be 
blinded to treatment assignment from randomisation 
until antibiotic discontinuation (‘ad terminum’). Thus, in 
the fixed short arm, all parties will be blinded until day 7, 
and in the individualised arm until the clinical require-
ments for discontinuation have been met. In the effort 
to avoid unblinding by the process of elimination after 
day 7, attending physicians and nurses will not be made 
aware of the specific algorithm defining criteria for anti-
biotic discontinuation in the individualised group. They 
will thus be allowed to view all CRP results, but they will 
not be able to predict when an individualised duration 
will end.
Blinded outcomes assessment and data analysis
Clinical data on all included patients will be collected 
regularly by study personnel and recorded in the elec-
tronic case report form (eCRF) and database (Secutrial 
V.4.8). HUG data managers, experienced in generating 
blinded reports, will then provide data exports to a blinded 
outcomes assessor and a blinded data analyst; these 
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exports will contain recoded (‘scrambled’) study iden-
tification numbers and no information on treatment 
assignments, allowing for both fully blinded outcomes 
assessment and data analysis.
Lifting the blind
Because (1) no experimental therapy will be given and 
(2) treating physicians will have the right to override 
the patient’s treatment duration assignment in the case 
of clinical worsening, it is not anticipated that any early 
lifting of the blind will be necessary. Nonetheless, instruc-
tions and the means to access the randomisation list 
overnight and on weekends will be available to the infec-
tious disease physician on call should early lifting of the 
blind be deemed necessary.
Primary and secondary outcome measures
The primary outcome will be the clinical failure rate in all 
arms at day 30. Clinical failure is defined by the presence 
of at least one of the following:
 ► Relapse: a recurrent bacteraemia due to the same 
bacterium occurring from the day of treatment 
cessation and through day 30;
 ► Local suppurative complication that was not present 
at infection onset (eg, renal abscess in pyelonephritis, 
empyema in pneumonia);
 ► Distant complications of the initial infection, defined 
by growth of the same bacterium causing the initial 
bacteraemia (as determined by antibiotic susceptibility 
profiling);
 ► The restarting of Gram-negative-directed antibiotic 
therapy after its initial discontinuation due to 
clinical worsening suspected to be due to the initial 
infecting organism and for which there is no alternate 
diagnosis/pathogen suspected;
 ► Death due to any cause through day 30.
Secondary outcomes include the incidence of clinical 
failure at days 60 and 90; all-cause mortality at days 30, 
60 and 90; the total number of antibiotic days; the inci-
dence of antibiotic-related adverse events through day 90 
(including C. difficile infection, a common by-product of 
antibiotic overconsumption); the incidence of the emer-
gence of bacterial resistance in those with recurrence; the 
number of patients in each arm whose assigned antibiotic 
duration was ‘overridden’ by physicians in the absence 
of clinical failure (and the reasons for these deviations) 
and length of hospital stay. Cost-effectiveness and other 
health-economic analyses will also be performed.
Additional subgroup analyses will be performed for 
main causative organisms, resistance patterns, involved 
organ systems, antibiotic regimens including single 
versus combination therapy and de-escalation. More-
over, risk factors for clinical failure will be determined, 
such as age, antibiotic choice, anatomic focus of primary 
infection, comorbidity status, infection acquisition type 
(community vs nosocomial), severity of illness at the time 
of diagnosis and so on.
Other definitions
Bacteraemias will be categorised as nosocomial if the first 
positive sample is taken ≥48 hours after hospital admis-
sion; otherwise they will be categorised as community 
acquired. Additionally, if the patient has been admitted 
to hospital in the preceding 30 days, transferred from 
another healthcare facility (eg, long-term care unit), is 
receiving chronic dialysis or has metastatic cancer, their 
bacteraemia will be considered healthcare associated.30
Severity of illness at the time of bacteraemia onset will be 
defined by the Quick SOFA Score (qSOFA), which can be 
determined for all patients (including non-ICU patients). 
The score consists of three variables and has a maximum 
of three points (one point each for systolic blood pres-
sure ≤100 mm Hg, respiratory rate ≥22 breaths/min and 
any altered mental state (Glasgow Coma Scale <15)); the 
presence of ≥2 points is associated with higher risks for 
mortality and extended ICU stay.31
study schedule
After randomisation, patients will be followed for a total 
of 90±21 days. An important principle of POC trials is 
that patients be allowed to remain in their normal clin-
ical setting; they are followed non-invasively for outcomes 
data. The only additional laboratory test that may be 
requested is later-phase CRP measurements if these have 
not already been ordered by treating physicians (on days 
8±2 and 12±2 in patients whose antibiotic therapy was not 
already discontinued).
On days 30, 60 and 90, clinical data necessary for 
determining the primary and secondary outcomes listed 
above will be collected. If on these days the patient is no 
longer hospitalised, he will be contacted by study staff 
by telephone and interviewed according to a structured 
questionnaire including the clinical information in the 
following section. In the event that a patient reports clin-
ical worsening at the time of follow-up, he will be asked 
to come for an in-person visit at the HUG’s Policlinique 
des maladies infectieuses, or respective outpatient clinics 
at CHUV and KSSG, respectively. The study’s schedule of 
assessments is shown in table 1.
Interim analyses
An interim analysis for safety will be performed after 
roughly 150 patients have reached 30 days of follow-up 
(described in more detail below). At this time, and if 
determined necessary, a non-blinded investigator will 
also assess the performance of the CRP as a marker for 
guiding durations. If the marker is proving either imprac-
tical (eg, logistically difficult to obtain) or its algorithm 
difficult to follow (eg, CRP initially decreases but not 
quite by 75%, then rises again due to another inflamma-
tory process), an alteration in the algorithm or in the arm 
itself will be explored. Any recommended changes will 
undergo review by all study investigators and methodol-
ogists, and any proposed amendment to the protocol will 
be submitted to the central ethics committee per usual 
routine.
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Table 1 Schedule of assessments. Day 1 is the first day of microbiologically efficacious antibiotic therapy
Study visit/observation point 1 2 3 4 5 6 7
Screening Randomisation Follow-up
Timeline (study day) 0–5 5 8 12 30 60 90
Window period (days) ±1 ±1 ±2 ±2 ±7 ±14 ±21
Informed consent X (X) (X) (X)
Entry criteria X
CRP measurement* (2 mL blood) X X
AEs reviewed X X
SAEs reviewed X X X X X
Other outcomes data collected X X X
*The CRP will not be requested in patients whose antibiotic therapy has already been discontinued.
AE, adverse events; CRP, C reactive protein; SAE, serious adverse events.
safety ‘checkpoint’ analyses
An initial safety ‘checkpoint’ analysis will be performed 
after 150 patients (roughly one-third of the target) have 
reached the 30-day follow-up mark to assess whether arms 
with shorter therapy durations (fixed short duration of 7 
days and individualised arm) could potentially result in 
worse clinical outcomes, specifically with increased clin-
ical failure. The outcomes assessment and data analysis 
for this assessment will be done in blinded fashion. If, 
however, results show a significant difference in outcomes 
in any arm, the blind will be lifted for the data analyst. 
(Blinding and unblinding of data will occur with the aid 
of the data manager, as described above.) Given the rela-
tively small number of patients to be included in the first 
safety analysis (necessarily reducing power), statistical 
support in the interpretation of the data will be provided 
by study statisticians.
Unblinded results will be forwarded to an indepen-
dent Safety Monitoring Board (SMB) for review. Should 
patients in either of the intervention arms demonstrate 
significantly worse clinical outcomes, recommendations 
made by the SMB will be followed. Other safety check-
points may be scheduled depending on the outcome of 
this first fixed analysis.
adverse events
An adverse event (AE) is any untoward medical occurrence 
in a subject that may occur during or after administration 
of a pharmaceutical product and does not necessarily 
have a causal relationship with the intervention. An AE 
can therefore be any unfavourable and unintended sign 
(including an abnormal laboratory finding), symptom or 
disease temporally associated with the study intervention, 
whether or not considered related to the study interven-
tion.
For the purposes of this study, whose focus is not on 
the choice of antibiotic but on its duration and within 
which only postmarket non-experimental antibiotics 
with well-established safety profiles will be used, only 
AE considered possibly, probably or certainly related to 
the antibiotic(s) being administered for the GNB will be 
recorded into the eCRF. The AE will thus be recorded 
during and in the 2 days following discontinuation of 
antibiotic therapy targeting the GNB. After that point 
and for the remainder of the study period, only symptom-
atic C. difficile infection and serious adverse events will be 
recorded in the eCRF.
sample size calculation
Previous observational studies and RCTs including 
patients with bacteraemia10 16 30 32 have demonstrated clin-
ical failure rates between 10% and 30% in settings with 
access to broad-spectrum antibiotics and resistance preva-
lences similar to those in Switzerland. The primary reason 
for failure in these and other studies is the lack of appro-
priate antibiotic therapy (either due to antimicrobial 
resistance or a delay in therapy initiation). Because this 
trial’s inclusion criteria require 5 days of microbiologically 
adequate antibiotic therapy at the time of randomisation, 
we assume the upper limit of ‘success’ or, inversely, the 
clinical failure will be 10% in both the control and inter-
vention arms. To establish non-inferiority, we will allow 
a difference up to 10% in the primary outcome. The 
chosen margin is wide because the expected gain from 
reducing the use of antibiotics is significant (decreased 
odds for antibiotic resistance, reduction in treatment 
adverse events, reduced medical costs by shorter length 
of hospital stay).9 Furthermore, as we will have excluded 
immunosuppressed patients and those with complicated 
infections, there will be decreased risk for life-threatening 
events and serious deterioration.
Further assuming a one-sided type 1 error (α) of 0.025, 
a power (ß) of 0.80, an attrition (loss to follow-up) of ~5% 
and potential treatment switching of ~12%, 167 patients 
will be needed in each of the three arms to prove non-in-
feriority, making the total sample size 500.
statistical analysis
We will perform the primary analysis on both the inten-
tion-to-treat (ITT) population (all patients randomised) 
and the per-protocol (PP) population (all patients 
adhering to the study protocol with no major deviations). 
8 Huttner A, et al. BMJ Open 2017;7:e017996. doi:10.1136/bmjopen-2017-017996
Open Access 
While ITT analyses are critical in all studies, in non-infe-
riority trials PP analyses take on a particularly important 
role in the effort to avoid commission of a type 2 error.33 
(One can imagine, for example, that non-adherence to 
the full 14-day antibiotic regimen could lead to this arm’s 
appearing generally less effective, thus lowering the bar 
for the two intervention arms.) In this particular study, 
however, the PP analysis will have another key role. As 
stated above, attending physicians will have the freedom 
to override their patients’ treatment duration assignments 
in the event of perceived clinical worsening. There may 
thus be some switching from intervention towards control 
arms (non-adherence to treatment assignment) with the 
risk of diluting the difference in clinical failure rates 
between the intervention groups and the control group 
and thus increasing the risk of incorrectly concluding 
non-inferiority of shorter antibiotic duration. The sample 
size has thus been increased to accommodate treatment 
switching of ~12% study wide or some 20 patients per 
group (see above).
Descriptive analyses with standard methods for 
randomised trials will be used to measure primary and 
secondary outcomes. Continuous variables will be 
compared between the three study arms with the use of 
Student's t-test or the Mann-Whitney U test, as appropriate; 
categorical variables will be compared with the χ2 test or 
Fisher’s exact test, as appropriate. To test the hypoth-
esis of non-inferiority for the prespecified margin of 10 
percentage points (see "Sample size calculation"), we will 
perform a generalised linear regression model with a log 
link and binomial distribution reporting risk differences 
of clinical failure between intervention arms compared 
with the control arm. The treatment assignment will be 
the main predictor with the control arm (‘fixed long’) 
as the reference and the model will be adjusted for the 
study centre.34 If some differences in the use of antibi-
otics are described between the three intervention arms, 
we will also adjust for it in the regression model. We will 
conclude non-inferiority of the ‘fixed short’ arm then of 
the ‘individualised’ arm compared with the ‘fixed long’ 
if the 95% upper bound is less than the 10 percentage 
points’ non-inferiority margin. With three centres, a 
mixed regression model is less appropriate. We will also 
present risk ratios or ORs with 95% CIs.
Missing data
Missing data will be taken into consideration using several 
methods, among them responder analysis, complete case 
analysis (modified ITT) and potentially multiple impu-
tation. These sensitivity analyses will be used to validate 
study findings.
data collection and management
Data management will be contracted to the Unité d’Inves-
tigation Clinique (UIC). Baseline and outcomes clinical 
data from primary source records will be entered into 
the eCRF for integration into the electronic database 
(SecuTrial platform). At the HUG site, in an effort to 
modernise data collection in this POC trial, the UIC data 
management team will work together with the DPI infor-
matics team to pilot algorithms for the regular transfer 
of coded, postrandomisation clinical data directly from 
DPI into the SecuTrial database, reducing both staffing/
resource use and the risk of manual transcription errors. 
At the peripheral sites (neither of which uses DPI), study 
investigators will enter data into SecuTrial.
The principal investigator will be responsible for over-
seeing the receipt, entering, cleaning, querying, analysis 
and storage of all data that accrue from the study by desig-
nated persons. For each set of data, quality control and 
triggers to computerised logic and/or consistency checks 
will be systematically applied to detect errors or omis-
sions. After integration of all corrections in the complete 
set of data, the database will be locked and saved before 
being released for statistical analysis. Each step of this 
process will be monitored through the implementation of 
individual passwords and/or regular backups to maintain 
appropriate database access and to guarantee database 
integrity.
All data will be coded: patients’ data will be identified 
by a unique study identification number containing no 
personally identifiable information (PII) in the eCRF. A 
separate confidential file containing PII will be stored in a 
secured (locked) location in accordance with data protec-
tion requirements. Only the sponsor representative, study 
investigators, the study monitor and the Ethics Commis-
sion will be granted access to the records.
observatIonal substudIes
nested prospective observational cohort study on recall and 
understanding after oral versus written informed consent
Background and rationale: oral consent with witness testimony
In line with the recent advice of the Geneva Ethics 
Commission and with OClin Art.8 al.1b, patients 
consenting to participate in this study may provide oral 
consent when an independent witness can sign testimony 
to that consent. The background and justification for this 
informed consent model are detailed below. The decision 
to obtain oral or written consent will be left to the discre-
tion of the including investigator and will depend on the 
clinical and cognitive state of the patient.
Very little is known about patient recall and under-
standing after oral versus written consent, whether that 
consent was granted for a research study or a clinical 
procedure; we therefore propose a nested study to 
compare these outcomes among the patients providing 
oral consent with those of patients providing written 
consent for participation in this study, as well as to 
outcomes of historical controls (patients providing 
written consent for participation in other trials, such as 
those followed by Chenaud et al.35 We know that recall 
and understanding in the weeks after written consent 
are not optimal; our hypothesis is that they will not 
differ much (will not be significantly worse) after oral 
consent.
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Box 1 Informed consent - recall and understanding post-
consent
 ► Do you recall agreeing to participate in this study?
 ► Do you recall the purpose of this study? (per information brochure: 
“The purpose of this research study is to compare 14 days of 
antibiotic therapy to either 7 days or an “individualized” number of 
days…for their efficacy and safety.”
 ► Do you recall the risks of the study? (per information brochure: 
“Rarely an additional blood draw may be needed to continue to 
measure the response to therapy. Blood draws can lead to bruising 
and pain at the point of puncture. The total loss of blood (2 ml, or 
half a teaspoon) is not higher than for a blood donation and thus not 
enough to cause medical problems in people with no underlying 
illness. An unknown risk cannot be excluded.”)
Nested oral consent study design, setting and population
All patients approached for inclusion in the "Point-of-
care, informatics-based randomised controlled trial for 
decreasing overuse of antibiotic therapy in Gram-nega-
tive bacteraemia" (PIRATE) study throughout its three 
trial sites will be eligible for participation in this nested, 
prospective observational cohort study. This substudy will 
begin and end in step with the larger PIRATE trial, thus 
patients are expected to be included from the spring of 
2017 through the spring of 2019.
Nested oral consent study outcomes
The primary outcome is the percentage of patients in both 
groups who recall granting informed consent to partici-
pate in the PIRATE trial on day 30 (±7 days). Secondary 
outcomes will include the same endpoint on days 60 (±14 
days) and 90 (±21 days), as well as the ability to recall the 
purpose and risks of the trial as stated in the information 
brochure at all named time-points. For these, the simple 
questionnaire in box 1 will be used. Another outcome will 
simply be the number of patients included in each arm, 
and the investigator’s cited reason for pursuing an oral 
versus written consent. Finally, we will perform correlation 
analyses for recall and understanding, looking at baseline 
demographic factors, other factors such as whether the 
patient asked a question during the initial information 
encounter,35 whether family members were present and 
whether an attending physician or family member signed 
the witness testimony.
Substudy statistical considerations
Given the hypothesis of non-inferiority in recall after oral 
versus written consent, a presumed recall after consent in 
the control (written) arm of roughly 80%,35 and assuming 
a significance (alpha) level and power of 5% and 80%, 
respectively, roughly 198 patients would be needed in 
each arm to demonstrate non-inferiority with a margin 
of 10%, a sample size achievable given the context of the 
larger PIRATE trial. Nonetheless, we appreciate that we 
will ultimately be relying on a convenience sample. This 
is because we cannot confirm that PIRATE trial inclusions 
by oral and written consent will occur at a 1:1 rate; patients 
will not be randomised to either mode of consent.
Descriptive statistics will be used to describe patient 
characteristics and measure recall outcomes in each arm. 
Continuous variables will be compared with the use of 
Student's t-test or the Mann–Whitney U test, as appro-
priate; categorical variables will be compared with the χ2 
test or Fisher’s exact test, as appropriate. Logistic or log 
binomial regression models, where appropriate, will be 
used for the correlation analyses described above.
observational study on excluded patients’ clinical outcomes
Background and rationale
Traditional RTCs have historically excluded patients who 
are ‘too old,’ ‘too sick’ and ‘too comorbid’; these exclu-
sions reduce their external validity and thus the relevance 
of their results for clinicians dealing with real patients. Paul 
et al recently provided a striking example of this problem: 
they observed the clinical outcomes of the 220 patients 
who were not included in a RCT comparing vancomycin 
to trimethoprim–sulfamethoxazole for severe methicil-
lin-resistant Staphylococcus aureus infections in comparison 
with those of the 252 patients who were included. Most 
patients were excluded because of an inability or unwill-
ingness to provide written informed consent. The clinical 
failure rate in this group was 80%, while only 33% of 
included patients experienced clinical failure. Within 
the trial, mortality in the vancomycin group was non-sig-
nificantly lower (mortality OR 0.76, 95% CI 0.36 to 1.62), 
but among excluded patients, mortality was significantly 
higher with vancomycin treatment (OR 2.63, 95% CI 1.04 
to 6.64).36
As described in the first pages of this protocol, POC 
randomised trials seek a greater inclusiveness and should 
thus theoretically provide stronger external validity. One 
particular aspect of the PIRATE trial is its option to allow 
witnessed, oral consent from patients who are too sick 
and/or tired to be able or willing to hand-sign a consent 
form. We hope that this will allow for a more inclusive trial 
and thus more methodologically robust and applicable 
outcome data. We therefore propose to follow excluded 
patients’ clinical outcomes (‘EPCO’), as Paul et al did, in 
an observational cohort study, but with the hypothesis 
that in this case, outcomes will be less divergent among 
included versus non-included patients.
EPCO study design, setting and population
All patients approached for but not included in the 
PIRATE trial will be eligible for participation in this 
prospective, multicentre observational cohort study. This 
study will begin and end in step with the larger PIRATE 
trial, thus patients are expected to be included from the 
spring of 2017 through the spring of 2019.
EPCO study outcomes
The primary outcome will be the same as that of the 
PIRATE trial: the rate of clinical failure rate, as defined 
above, at day 30±7 days among excluded patients 
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receiving 7 versus 14 days (vs other durations) of anti-
biotic therapy. Secondary outcomes will include the 
median duration of antibiotic therapy, length of hospital 
stay and the reasons for exclusion (consent, patient char-
acteristics and infection characteristics). We will further 
assess associations, if any, between baseline patient and 
infection characteristics and willingness or ability to 
provide informed consent, whether oral or written.37–41 
Given the difficulties of obtaining follow-up information 
in this type of population, patients’ clinical outcomes 
will be followed only through day 30±7 (with day 1 being 
the first day of microbiologically appropriate antibiotic 
therapy).
EPCO study statistical considerations
As described above, we estimate that included patients 
will experience a clinical success rate between approxi-
mately 80% and 90%. Assuming a significance (alpha) 
level of 5%, power of 80% and attrition (inability to glean 
follow-up information) of roughly 20%, approximately 90 
patients will be needed to enable the detection of at least 
a 20% difference in the primary outcome rate between 
the observation cohort and the PIRATE RCT.
Descriptive statistics will be used to describe patient 
and infection characteristics. Continuous variables 
will be compared with the use of Student's t-test or 
the Mann-Whitney U test, as appropriate; categorical 
variables will be compared with the χ2 test or Fisher’s 
exact test, as appropriate. Unadjusted ORs for the 
comparison between the different antibiotic durations 
in each cohort (observational and PIRATE trial) will 
be computed with 95% CIs and compared using the 
Breslow-Day test.
Data handling for the EPCO observational study
No data from excluded patients will be entered into 
the PIRATE eCRF and database. EPCO patients will be 
identified by means of an EPCO study number, and no 
personally identifying information will be transcribed 
into the EPCO CRF, which will be stored under lock and 
key, independently and apart from PIRATE data. EPCO 
data will be entered into a separate, password-protected 
electronic database that will serve the EPCO study only.
MonItorIng
External monitoring will be performed according to 
International Conference on Harmonisation (ICH) 
Good Clinical Practice (GCP) by the Unité d’investiga-
tion Clinique of the HUG. Following a monitoring plan 
and written standard operating procedures (SOP), the 
monitors will verify that the clinical trial is conducted 
and data are generated, documented and reported in 
compliance with the protocol, GCP and the applicable 
regulatory requirements. The investigating team will 
provide direct access to all trial-related source data, docu-
ments and reports for the purpose of monitoring and 
auditing by the sponsor and inspection by local and regu-
latory authorities.
ethIcs and dIsseMInatIon
Study investigators will ensure that this study is conducted 
according to the principles of the latest revision of the 
Declaration of Helsinki (Fortaleza, Brazil, October 2013) 
and in full conformity with the ICH GCP, the require-
ments of the Swiss Human Research Act (HRA;810.30, 
2011) and the Swiss ordinance on clinical trials (ClinO; 
810.305, 2013) and local regulatory requirements.
Informed consent
All patients will be informed of the study by means of a 
written information brochure, per usual ICH standards, 
with full details of the study including its risks and bene-
fits (see information brochure, V.1.1, dated 3 August 
2017) before enrolment. In accordance with the recent 
advice of the Geneva Ethics Commission, and in line with 
ClinO 810.305, we will allow consenting patients to grant 
oral consent when written consent cannot be given due 
to bodily or cognitive reasons and when an independent 
witness can provide signed testimony to that oral consent. 
The substudy detailed above will compare patients’ post-
consent recall and understanding of the study after oral 
with written consent.
ethics committee review
The protocol, IC, and all other study documents have 
received full approval from the Geneva Cantonal Ethics 
Commission (lead) as well as the Ethics Commissions of 
the peripheral sites in Lausanne and St Gallen. Modifi-
cations to the protocol will be submitted to these ethics 
commissions as formal amendments before being imple-
mented.
dissemination
A manuscript with the results of the primary study will 
be published in a peer-reviewed journal. Separate manu-
scripts will be written on each of the substudies and 
on some secondary outcomes, and these will also be 
submitted for publication in peer-reviewed journals.
On completion of the trial, and after publication of the 
primary manuscript, data requests can be submitted to 
the researchers at the HUG.
Author affiliations
1Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland
2Infection Control Program, Geneva University Hospitals, Geneva, Switzerland
3Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St 
Gallen, St Gallen, Switzerland
4Department of Medicine, Infectious Diseases Service, Lausanne University Hospital, 
Lausanne, Switzerland
5CRC & Division of Clinical Epidemiology, Department of Health and Community 
Medicine, University Hospitals Geneva, Geneva, Switzerland
6Department of Internal Medicine, Geneva University Hospital, Geneva, Switzerland
Acknowledgements The authors thank Drs Bernard Hirschel, Benedikt Huttner 
and Thomas Perneger for their thoughtful advice on design and implementation.
Contributors AH, WA, PYB, EvD, SH and LK designed the study; AH, WA and AGA 
wrote the main randomised controlled trial protocol; AR assisted in the design of 
the EPCO substudy and EvD in the design of the informed consent nested study; AH 
wrote the protocol manuscript. All authors approved the manuscript.
 11Huttner A, et al. BMJ Open 2017;7:e017996. doi:10.1136/bmjopen-2017-017996
Open Access
Funding Swiss National Science Foundation, 74th National Research Program 
'Smarter Health Care' (no. 407440_167359) protocol version 1.2, dated 
27.03.2017.
Competing interests None declared.
Ethics approval Geneva Cantonal Ethics Commission.
Provenance and peer review Not commissioned; peer reviewed for ethical and 
funding approval prior to submission.
Open Access This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2017. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
references
 1 Huttner A, Harbarth S, Carlet J, et al. Antimicrobial resistance: a 
global view from the 2013 World Healthcare-Associated Infections 
Forum. Antimicrob Resist Infect Control 2013;2:31.
 2 WHO Antimicrobial Fact Sheet. 2015 http://www. who. int/ 
mediacentre/ factsheets/ fs194/ en/.
 3 Swiss Federal Office of Public Health: responses to the antimicrobial 
resistance threat. 2015 http://www. bag. admin. ch/ themen/ 
internationales/ 11287/.
 4 Holmes AH, Moore LS, Sundsfjord A, et al. Understanding the 
mechanisms and drivers of antimicrobial resistance. Lancet 
2016;387:176–87.
 5 Zarkotou O, Pournaras S, Tselioti P, et al. Predictors of mortality 
in patients with bloodstream infections caused by KPC-producing 
Klebsiella pneumoniae and impact of appropriate antimicrobial 
treatment. Clin Microbiol Infect 2011;17:1798–803.
 6 Chastre J, Wolff M, Fagon JY, et al. PneumA Trial Group. Comparison 
of 8 vs 15 days of antibiotic therapy for ventilator-associated 
pneumonia in adults: a randomized trial. JAMA 2003;290:2588–98.
 7 Havey TC, Fowler RA, Daneman N. Duration of antibiotic therapy 
for bacteremia: a systematic review and meta-analysis. Crit Care 
2011;15:R267.
 8 Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for 
the diagnosis and management of intravascular catheter-related 
infection: 2009 Update by the Infectious Diseases Society of 
America. Clin Infect Dis 2009;49:1–45.
 9 Sandberg T, Skoog G, Hermansson AB, et al. Ciprofloxacin for 
7 days versus 14 days in women with acute pyelonephritis: a 
randomised, open-label and double-blind, placebo-controlled, non-
inferiority trial. Lancet 2012;380:484–90.
 10 Tellier G, Niederman MS, Nusrat R, et al. Clinical and bacteriological 
efficacy and safety of 5 and 7 day regimens of telithromycin once 
daily compared with a 10 day regimen of clarithromycin twice daily 
in patients with mild to moderate community-acquired pneumonia. J 
Antimicrob Chemother 2004;54:515–23.
 11 File TM, Mandell LA, Tillotson G, et al. Gemifloxacin once daily 
for 5 days versus 7 days for the treatment of community-acquired 
pneumonia: a randomized, multicentre, double-blind study. J 
Antimicrob Chemother 2007;60:112–20.
 12 Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course 
levofloxacin for community-acquired pneumonia: a new treatment 
paradigm. Clin Infect Dis 2003;37:752–60.
 13 Runyon BA, McHutchison JG, Antillon MR, et al. Short-course versus 
long-course antibiotic treatment of spontaneous bacterial peritonitis. 
A randomized controlled study of 100 patients. Gastroenterology 
1991;100:1737–42.
 14 Chaudry ZI, Nisar S, Ahmed U. Short course of antibiotic treatment 
in spontaneous bacterial peritonitis: a randomized controlled 
study. Journal of the College of Physicians and Surgeons Pakistan 
2000;10:284–8.
 15 Hepburn MJ, Dooley DP, Skidmore PJ, et al. Comparison of short-
course (5 days) and standard (10 days) treatment for uncomplicated 
cellulitis. Arch Intern Med 2004;164:1669–74.
 16 Oliveira CF, Botoni FA, Oliveira CR, et al. Procalcitonin versus 
C-reactive protein for guiding antibiotic therapy in sepsis: a 
randomized trial. Crit Care Med 2013;41:2336–43.
 17 Adamina M, Steffen T, Tarantino I, et al. Meta-analysis of the 
predictive value of C-reactive protein for infectious complications in 
abdominal surgery. Br J Surg 2015;102:590–8.
 18 Lin KH, Wang FL, Wu MS, et al. Serum procalcitonin and C-reactive 
protein levels as markers of bacterial infection in patients with liver 
cirrhosis: a systematic review and meta-analysis. Diagn Microbiol 
Infect Dis 2014;80:72–8.
 19 Torres A, Ramirez P, Montull B, et al. Biomarkers and community-
acquired pneumonia: tailoring management with biological data. 
Semin Respir Crit Care Med 2012;33:266–71.
 20 Nobre V, Harbarth S, Graf JD, et al. Use of procalcitonin to shorten 
antibiotic treatment duration in septic patients: a randomized trial. 
Am J Respir Crit Care Med 2008;177:498–505.
 21 Wacker C, Prkno A, Brunkhorst FM, et al. Procalcitonin as a 
diagnostic marker for sepsis: a systematic review and meta-analysis. 
Lancet Infect Dis 2013;13:426–35.
 22 Uçkay I, Garzoni C, Ferry T, et al. Postoperative serum pro-calcitonin 
and C-reactive protein levels in patients with orthopedic infections. 
Swiss Med Wkly 2010;140:w13124.
 23 Havey TC, Fowler RA, Pinto R, et al. Duration of antibiotic therapy 
for critically ill patients with bloodstream infections: A retrospective 
cohort study. Can J Infect Dis Med Microbiol 2013;24:129–37.
 24 Corona A, Wilson AP, Grassi M, et al. Prospective audit of 
bacteraemia management in a university hospital ICU using a general 
strategy of short-course monotherapy. J Antimicrob Chemother 
2004;54:809–17.
 25 Bouadma L, Luyt CE, Tubach F, et al. PRORATA trial group. Use of 
procalcitonin to reduce patients' exposure to antibiotics in intensive 
care units (PRORATA trial): a multicentre randomised controlled trial. 
Lancet 2010;375:463–74.
 26. de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety 
of procalcitonin guidance in reducing the duration of antibiotic 
treatment in critically ill patients: a randomised, controlled, open-
label trial. Lancet Infect Dis 2016;16:819–27.
 27. Albrich WC, Harbarth S. Pros and cons of using biomarkers versus 
clinical decisions in start and stop decisions for antibiotics in the 
critical care setting. Intensive Care Med 2015;41:1739–51.
 28. Schuetz P, Briel M, Christ-Crain M, et al. Procalcitonin to guide 
initiation and duration of antibiotic treatment in acute respiratory 
infections: an individual patient data meta-analysis. Clin Infect Dis 
2012;55:651–62.
 29. Reinhart K, Bauer M, Riedemann NC, et al. New approaches to 
Sepsis: molecular diagnostics and biomarkers. Clin Microbiol Rev 
2012;25:609–34.
 30. Fitzpatrick JM, Biswas JS, Edgeworth JD, et al. Gram-negative 
bacteraemia; a multi-centre prospective evaluation of empiric 
antibiotic therapy and outcome in English acute hospitals. Clin 
Microbiol Infect 2016;22:244–51.
 31. Angus DC, Seymour CW, Coopersmith CM, et al. A framework for 
the Development and Interpretation of Different Sepsis definitions 
and clinical criteria. Crit Care Med 2016;44:e113–e121.
 32. Pittet D, Li N, Wenzel RP. Association of secondary and polymicrobial 
nosocomial bloodstream infections with higher mortality. Eur J Clin 
Microbiol Infect Dis 1993;12:813–9.
 33. Detry MA, Lewis RJ. The intention-to-treat principle: how to 
assess the true effect of choosing a medical treatment. JAMA 
2014;312:85–6.
 34. Food & Drug Administration. Guidance for Industry. E9 Statistical 
Principles for Clinical Trials 1998 http://www. fda. gov/ downloads/ 
drugs/./ guidances/ ucm073137. pdf.
 35. Chenaud C, Merlani P, Luyasu S, et al. Informed consent for research 
obtained during the intensive care unit stay. Crit Care 2006;10:R170.
 36. Paul M, Bronstein E, Yahav D, et al. External validity of a randomised 
controlled trial on the treatment of severe infections caused by 
MRSA. BMJ Open 2015;5:e008838.
 37. Balajonda N, Bisanar TL, Mathew JP, et al. Determinants of a 
subject's decision to participate in clinical anesthesia research. 
Anesth Analg 2013;116:448–54.
 38. Gayet-Ageron A, Rudaz S, Perneger T. Biobank attributes associated 
with higher patient participation: a randomized study. Eur J Hum 
Genet 2016;25:31–6.
 39. Knoester PD, Belitser SV, Deckers CL, et al. Recruitment of a cohort 
of lamotrigine users through community pharmacists: differences 
between patients who gave informed consent and those who did 
not. Pharmacoepidemiol Drug Saf 2005;14:107–12.
 40. Beebe TJ, Ziegenfuss JY, Jenkins SM, et al. Who doesn't authorize 
the linking of survey and administrative health data? A general 
population-based investigation. Ann Epidemiol 2011;21:706–9.
 41. Huang N, Shih SF, Chang HY, et al. Record linkage research and 
informed consent: who consents? BMC Health Serv Res 2007;7:18.
